NCT02899611View on ClinicalTrials.gov

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Epilepsy
Interventions
DRUG

Valproate

ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.

Trial Locations (1)

3010

St. Vincent Hospital, Melbourne

Sponsors
All Listed Sponsors
collaborator

Neuroscience Trials Australia

OTHER

lead

Cerebral Therapeutics LLC

INDUSTRY

NCT02899611 - A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures | Biotech Hunter | Biotech Hunter